TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report released on Tuesday morning. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

Shares of TXMD stock opened at $1.35 on Tuesday. The business has a fifty day moving average of $1.53 and a 200 day moving average of $1.73. TherapeuticsMD has a 1 year low of $1.15 and a 1 year high of $2.75.

Institutional Investors Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP raised its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is currently owned by institutional investors and hedge funds.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.